Alessandro Zannini
Overview
Explore the profile of Alessandro Zannini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al.
Nat Commun
. 2023 Nov;
14(1):7129.
PMID: 37932286
No abstract available.
2.
Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al.
Nat Commun
. 2023 Oct;
14(1):6777.
PMID: 37880212
Reprogramming of amino acid metabolism, sustained by oncogenic signaling, is crucial for cancer cell survival under nutrient limitation. Here we discovered that missense mutant p53 oncoproteins stimulate de novo serine/glycine...
3.
Campaner E, Zannini A, Santorsola M, Bonazza D, Bottin C, Cancila V, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33371412
Tumor organoids are tridimensional cell culture systems that are generated in vitro from surgically resected patients' tumors. They can be propagated in culture maintaining several features of the tumor of...
4.
Bertolio R, Napoletano F, Mano M, Maurer-Stroh S, Fantuz M, Zannini A, et al.
Nat Commun
. 2019 Mar;
10(1):1326.
PMID: 30902980
Sterol regulatory element binding proteins (SREBPs) are a family of transcription factors that regulate lipid biosynthesis and adipogenesis by controlling the expression of several enzymes required for cholesterol, fatty acid,...
5.
Zannini A, Rustighi A, Campaner E, Del Sal G
Front Oncol
. 2019 Mar;
9:94.
PMID: 30873382
Cellular choices are determined by developmental and environmental stimuli through integrated signal transduction pathways. These critically depend on attainment of proper activation levels that in turn rely on post-translational modifications...
6.
Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L, et al.
Nat Cell Biol
. 2017 Dec;
20(1):28-35.
PMID: 29255172
Tumour-associated p53 missense mutants act as driver oncogenes affecting cancer progression, metastatic potential and drug resistance (gain-of-function) . Mutant p53 protein stabilization is a prerequisite for gain-of-function manifestation; however, it...
7.
Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y, et al.
Nat Commun
. 2017 Jun;
8:15772.
PMID: 28598431
The prolyl isomerase PIN1, a critical modifier of multiple signalling pathways, is overexpressed in the majority of cancers and its activity strongly contributes to tumour initiation and progression. Inactivation of...
8.
Sorrentino G, Ruggeri N, Zannini A, Ingallina E, Bertolio R, Marotta C, et al.
Nat Commun
. 2017 Jan;
8:14073.
PMID: 28102225
The Hippo pathway is an oncosuppressor signalling cascade that plays a major role in the control of cell growth, tissue homoeostasis and organ size. Dysregulation of the Hippo pathway leads...
9.
Rustighi A, Zannini A, Campaner E, Ciani Y, Piazza S, Del Sal G
Cell Death Differ
. 2016 Nov;
24(2):200-211.
PMID: 27834957
Mammary gland development, various stages of mammary tumorigenesis and breast cancer progression have the peptidyl-prolyl cis/trans isomerase PIN1 at their centerpiece, in virtue of the ability of this unique enzyme...
10.
Taccioli C, Sorrentino G, Zannini A, Caroli J, Beneventano D, Anderlucci L, et al.
Oncotarget
. 2015 Oct;
6(36):38854-65.
PMID: 26513174
Targeted anticancer therapies represent the most effective pharmacological strategies in terms of clinical responses. In this context, genetic alteration of several oncogenes represents an optimal predictor of response to targeted...